Boston, Mass.-based eClinical technology company PHT inked a partnership agreement with UK-based contract research organization (CRO) ICON. The deal allows for ICON to use of PHT’s LogPad electronic patient diary (ePRO) device and SitePad Tablet, a site-based electronic data capture (EDC) product. In exchange, ICON will allow PHT’s clients to use the CRO’s Lifecycle Science Group to aid them in the design and implementation of studies using interactive response (both voice and web) and ePRO technology using ICOPhone and other ICON technologies. The companies have already won three new trials under the partnership. "Strategic partnerships are a key element of PHT's growth strategy, and our partnership with ICON has delivered immediate benefits to the clients of both companies," stated Phil Lee, PHT's president and chief executive officer.
New York, N.Y.-based Medidata Solutions won a contract with CRO Clinsys Clinical Research for the use of Medidata Rave, its EDC and trial management technology. The agreement falls under Medidata’s ASPire-to-Win program, the company’s non-exclusive service-based model. It will allow Clinsys to capture, manage and report its for delivery to its sponsor clients in the U.S., Europe and India. Clinsys stated its customers prefer web-based, customizable solutions instead of “one type fits all” platforms and chose Medidata partly for its flexibility. Medidata Rave will be implemented into Clinsys Global Project Solution (or Clinsys GPS), its internal clinical project management system. The CRO plans to use Rave in multiple phase II and III global studies. “As EDC adoption continues to grow within highly specialized therapeutic areas, we are pleased to partner with Clinsys, a company with the expertise necessary to modernize these types of trials with the implementation of Medidata Rave,” said Graham Bunn, vice president of Global CRO Partnerships at Medidata Solutions.
OmniComm Systems has landed a deal with the National Cancer Institute (NCI) cancer center, City of Hope, for the use of its EDC system TrialMaster for many of its oncology trials. The first trial will enroll up to 132 subjects at 17 sites around the world. The trial will be run by City of Hope for the California Cancer Consortium. Both OmniComm Systems and the City of Hope developed a library of 50 reusable eCRFs from the NCI’s many resources. The CRF’s meet the various collection and submission requirements of the NCI and supports the NCI’s Cancer Therapy Evaluation Program (CTEP) guidelines. Built-in are standardized methods for coding disease classifications, adverse events and a patient’s prior treatments. City of Hope is also planning a second trial using Trial Master for a breast cancer trial. “We are proud that City of Hope has chosen to leverage our TrialMaster solution to help standardize and accelerate the search for new cancer treatments. City of Hope has been a great partner to work with and they have helped us to establish leading tools and best practices in support of cancer research,” said Ken Light, senior vice president of Professional Services for OmniComm Systems.